Vince Martin

Vince Martin

Vince Martin has written investing advice for several years, covering stocks across a range of industries. A former registered representative, Martin saw the dot-com bubble inflate and burst in real time, creating a healthy respect for downside risk. He splits his time between Chicago and rural Wisconsin with his wife and three dogs.

Recent Articles

The Key Question Surrounding XpresSpa Group Right Now

XSPA stock soared as the company pivoted to in-airport coronavirus testing. But even if the pivot works, it's unclear what comes next.

10 Growth Stocks That Crashed Despite Strong Earnings

Growth stocks have been among the biggest losers in the recent sell-off. For these 10 stocks, even impressive quarters weren't enough.

Post-Bankruptcy, Whiting Petroleum an Intriguing Choice for Oil Bulls

Bankruptcy improved Whiting's balance sheet. As a result, the "new" WLL stock has a chance to provide solid returns – if crude cooperates.

4 Energy Stocks to Buy That Truly Stand Out

Energy stocks continue to disappoint. But for investors still interested in the space, these four stocks have distinctive bull cases.

As Its Vaccine Dreams Fade, Inovio Stock Will Keep Retreating

INO stock has pulled back some 72% from its highs. But the fade makes sense, and even at a cheaper price the stock still looks like an avoid.

10 Buyout Stocks With Long-Term Potential

The novel coronavirus pandemic brought M&A to a halt. But as normalcy returns, so may acquisitions — and these 10 buyout stocks could benefit.

4 Overvalued Stocks to Avoid Until a Pullback

The names most often cited as overvalued stocks have been this market's big winners. These 4 stocks perhaps don't look expensive — but are.

Don’t Discount the Bears On Sorrento Stock

SRNE stock has been the target of a so-called "bear raid." But shorts make good points, and red flags remain for Sorrento.

7 Penny Stocks Under $4 Worth a Look

Investors looking for penny stocks to buy need to be cautious, as the group is usually dangerous. But these 7 names look attractive.

Ocugen Needs Too Much Time and Too Much Cash

OCGN stock has held up despite the failure of what was its flagship drug. The remaining pipeline simply isn't strong enough for investors to risk more capital.